Navigation Links
TCT 2010 to have significant impact on interventional cardiology practices and patient care
Date:4/13/2010

NEW YORK, NY -- APRIL 13, 2010 TCT 2010 (Transcatheter Cardiovascular Therapeutics) will provide significant clinical research updates to technologies and practices in interventional cardiology that will directly affect patient care.

The important role of interventional cardiology has figured prominently in recent current events with the announcement that former President Clinton received a heart stent in February at New York-Presbyterian Hospital, followed by the reporting of clinical trial data showing promising results for a heart valve repair device that is inserted via a catheter.

At TCT 2010 (September 21-25 in Washington, DC), late breaking data from clinical trials on the next generation of stents, valve repair and replacement, and the interactions and effectiveness of new medicines will shed light on the best ways to treat patients.

"Catheter-based valve repair and replacement, novel stents, and the effectiveness of various drugs used to treat heart disease are going to be among the major topics at TCT this year," said Gregg W. Stone, MD, Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation. TCT is organized by the Cardiovascular Research Foundation.

"Non-surgical aortic valve replacement has the potential to be life saving for people who are at high risk for open heart surgery," Stone said. "As the population ages, this technique may dramatically benefit the quality of life for patients whose aortic valves (the valve through which blood passes from the heart to the rest of the body) fail to function properly. We are hopeful that new trial data that will be presented at TCT will usher in the field of non-operative aortic valve replacement."

This year, TCT will also provide a new program, "TCT in 3," designed specifically for the busy interventional practitioner, which features a concentrated curriculum in a shorter 3 day time frame from Thursday, September 23 through Saturday, September 25. Highlights include live cases, late breaking trials and practice management sessions.

And once again, the conference will feature specific tracks for Cardiac Surgeons and Nurses and Technologists. The Surgeons Course will provide instruction on percutaneous valve repair, hybrid (joint) surgical and interventional approaches to heart disease, percutaneous aortic aneurysm repair methods, with an in-depth course on advanced surgical techniques. The 19th Annual Nurse and Technologist Symposium will detail new trends and cath lab procedures essential for the allied health care professional.

In 2009, TCT was held for the first time in San Francisco, where it attracted record numbers of attendees. 99.4% of physician attendees surveyed stated that TCT increased their knowledge to improve their practice.


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Sunquest Announces Significant Speaker Schedule for HIMSS 2010
2. Announcing New Book 'Ultimate Procrastination Cure', with a Significantly Different Approach to Stop Procrastinating
3. Mortality rates for pediatric rheumatology patients significantly lower than previously reported
4. Digital mammography delivers significantly less radiation than conventional mammography
5. Counterfeit Internet drugs pose significant risks and discourage vital health checks
6. Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders
7. Study finds significantly worse outcomes in cancer patients with cognitive impairment
8. New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums
9. MyCareTeam™ Significantly Extends Diabetes Offering to Include Management of Hypertension, Obesity, and Congestive Heart Failure
10. Add Drama and Lift Spirits While Significantly Reducing Energy Cost; Peachtree Introduces the Evolution Series, LED, Energy Efficient Wall Sconce
11. Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
Breaking Medicine Technology: